BEAM Biotechnology · Gene editing · Pre-commercial · Clinical stage · Thesis updated July 19, 2026

Beam liver edit gains a real path

BEAM-302 now has FDA alignment for an accelerated approval path in AATD.
The same liver delivery system could support BEAM-301 for GSD1a and BEAM-304 for PKU.
Risto-cel could reach a BLA filing as early as year-end 2026, but sickle cell is already crowded.
Beam had an accumulated deficit of $1.7 billion as of March 31, 2026, so funding still matters.
Patent rulings helped in March 2026, but appeals and a Toolgen case keep the IP risk alive.

01 Running thesis

AATD moved to the front

Beam’s story changed in Q1 2026. BEAM-302, its liver-targeted treatment for Alpha-1 Antitrypsin Deficiency, showed rapid gains in total and functional AAT. The FDA also aligned with Beam on an accelerated approval pathway using AAT biomarkers over 12 months, with 60 mg as the selected dose.

That matters beyond one disease. If BEAM-302 keeps working, it gives real human support to Beam’s in vivo LNP platform. In plain English, that is the delivery system that carries the base editor into the liver. That same idea backs BEAM-301 for GSD1a and BEAM-304 for PKU.

The bear case did not go away. The pivotal BEAM-302 cohort has not started yet, and Beam still needs to enroll 50 more patients and prove safety and benefit in a wider group. Risto-cel also faces approved sickle cell gene therapies, so good clinical data may not be enough for strong sales.

The stock’s setup is still high risk. Beam has no approved products, large losses, and a valuation that depends on future trial wins. The next 12 months should be busy, with the BEAM-302 pivotal start, possible risto-cel BLA filing, BEAM-301 data, and a BEAM-304 IND all on the watch list.

May 2026▲BEAM-302 cleared a major overhang with positive AATD data and FDA alignment on an accelerated approval pathway. March 2026 PTAB rulings also helped Beam’s IP position, though appeals and Toolgen remain open.

Feb 2026▲Beam added BEAM-304 for PKU and pointed to an IND filing in 2026. Management also highlighted risto-cel manufacturing advantages and a Sixth Street facility of up to $500 million.

Feb 2026▲The FY2025 10-K set a possible risto-cel BLA filing as early as year-end 2026. Beam also received $255.1 million from the Orbital deal and reported Pfizer’s opt-in to a liver-targeted candidate.

Nov 2025▲Updated BEACON data showed strong fetal hemoglobin and lower sickling HbS in 26 patients. The pending Bristol Myers Squibb acquisition of Orbital also pointed to a possible cash boost.

Aug 2025▲More BEAM-101 and BEAM-302 data supported clinical momentum. The next major BEAM-302 update shifted to early 2026, keeping the focus on the liver platform.

May 2025▲Initial BEAM-302 human data gave the first proof of concept for Beam’s in vivo LNP base editing platform. A $471.2 million capital raise also strengthened the cash position.

Feb 2025▲The 2024 10-K showed early BEAM-101 clinical proof of concept in sickle cell disease. The offset was a more cautious cash runway statement after year-end cash of $850.7 million.

Nov 2024→Beam reported cash runway into 2027 and gave context that a BEAM-101 trial death was likely tied to busulfan conditioning, not the editing therapy. The thesis stayed positive but safety risk remained clear.

02 Business model

Research funded by partners

Beam does not sell an approved drug today. Its revenue comes from license and collaboration deals, including work with Pfizer, Apellis, and Orbital Therapeutics. For the year ended December 31, 2025, Beam recognized $139.7 million of license and collaboration revenue.

The company is trying to turn base editing into medicines. Base editing aims to change one DNA letter without cutting both DNA strands. That may lower some risks versus older gene-editing methods, but it still needs more proof in people.

Cash comes from several places: stock sales, partner payments, and debt. Beam also received $255.1 million in cash when Bristol Myers Squibb bought Orbital Therapeutics in December 2025. A Sixth Street credit facility can provide up to $500 million, and management said the expected minimum draw of $200 million would extend runway into mid-2029.

Manufacturing is part of the plan. Beam has invested in a 100,000 sq. ft. cGMP manufacturing facility so it can control production and timing for trials. That could help if risto-cel reaches launch, but scaling complex genetic medicines is still hard.

03 Product portfolio

Two platforms, several shots

Growth engine

BEAM-302 for AATD

This is the lead in vivo liver program. Positive Q1 2026 data and FDA alignment on an accelerated approval path make the H2 2026 pivotal cohort the main near-term test.

Growth engine

Risto-cel for sickle cell disease

Risto-cel is an ex vivo stem cell therapy in the BEACON trial. ASH 2025 data showed mean fetal hemoglobin above 60% and mean sickling HbS below 40%, and Beam expects a BLA filing as early as year-end 2026.

Option

BEAM-301 for GSD1a

BEAM-301 is another liver-targeted base editor. Initial clinical data are expected in 2026 and could show whether the in vivo platform works outside AATD.

Option

BEAM-304 for PKU

BEAM-304 is a new LNP-delivered base editor for phenylketonuria. Beam plans to file an IND in 2026, starting with the R408W mutation.

Option

ESCAPE and BEAM-103

This program aims to improve conditioning, the harsh prep step before some cell therapies. Beam expects dosing in the BEAM-103 healthy volunteer trial to complete in the first half of 2026.

Option

BEAM-201 for T-ALL

BEAM-201 is an allogeneic CAR-T program for T-ALL. It remains deprioritized for internal development, so it is not central to the current thesis.

04 Business segments

One revenue bucket

License and collaboration revenue100%modest

Product revenue0%flat

Beam reports as one operating segment. For 2025, revenue came from license and collaboration revenue, while product sales were zero because Beam had no approved products.

05 Risk factors

What could still break

BEAM-302 pivotal miss

High impact · Medium odds

BEAM-302 is now the clearest value driver. The Q1 2026 data were promising, but the pivotal cohort has not started yet. The key question is whether the 60 mg dose keeps its safety and biomarker profile across 50 additional patients.

We watchStart date, enrollment speed, 12-month AAT biomarker results, and any serious adverse events in the pivotal cohort.

Risto-cel launch squeeze

High impact · Medium odds

Risto-cel may have manufacturing advantages, including a median mobilization cycle of one in management’s comments. But sickle cell gene therapy is already competitive, with approved products on the market. Beam could win approval and still face slow adoption.

We watchBLA timing, FDA questions, manufacturing release metrics, and early signs of patient and center demand.

Off-target editing or durability problem

High impact · Medium odds

Base editing is still a young technology. Trials could find edits in the wrong places, immune reactions, liver safety issues, or benefits that fade over time. Any one of those could hurt more than one program because Beam reuses the same platform ideas.

We watchLong-term follow-up, liver enzyme signals, off-target analysis, and durability of AAT, HbF, and disease markers.

Patent fight returns

Medium impact · Medium odds

The March 2026 PTAB ruling favored the Boston Licensing Parties tied to Beam’s optioned IP over the University of California. That helped, but the decision can be appealed. The PTAB also resumed a separate interference with Toolgen.

We watchAny University of California appeal and new PTAB actions in the Toolgen interference.

Funding and debt pressure

Medium impact · Medium odds

Beam had an accumulated deficit of $1.7 billion as of March 31, 2026. It has runway support from cash, collaborations, the Orbital cash payment, and the Sixth Street facility, but development and launch work can burn cash quickly. Restrictive debt covenants could limit flexibility if trials slip.

We watchQuarterly cash balance, operating cash burn, Sixth Street drawdowns, covenant disclosures, and any new equity raise.

06 Quick answers

In one breath

Does Beam Therapeutics have an approved product?

No. Beam is still pre-commercial, which means it has no approved medicines for sale. Its revenue today comes from license and collaboration deals, not product sales.

What is Beam’s most important program right now?

BEAM-302 for AATD is the main focus after positive Q1 2026 data and FDA alignment on an accelerated approval pathway. The next big step is starting the pivotal cohort in the second half of 2026.

Why does risto-cel matter if BEAM-302 is leading the story?

Risto-cel could be Beam’s first BLA filing, as early as year-end 2026. It also gives Beam a second major clinical path, but the sickle cell market is competitive.

What is base editing in simple terms?

Base editing is a way to change one DNA letter. Beam’s goal is to fix or silence disease-causing genes without making a full double-strand DNA cut.